New Combination Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Clinical Benefit in Stage III Non-Small Cell Lung Cancer (NSCLC) and Reinforce Long-Term Survival in Metastatic NSCLC
First Combination Data in Stage III NSCLC from KEYNOTE-799 Showed KEYTRUDA Plus Concurrent Chemoradiation Achieved Objective Response Rate of 67.0% and 56.6% in Two Cohorts
In the Final Analysis of KEYNOTE-189, KEYTRUDA in Combination with Chemotherapy Reduced the Risk of Death by 44% Versus Chemotherapy and at Two Years, Demonstrated a Sustained, Long-Term Survival Benefit in Metastatic NSCLC
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from two studies from the company’s leading lung cancer research program.
Media Contacts:
Pamela Eisele
(267) 305-3558
Justine Moore
(908) 740-6449
Investor Contacts:
Peter Dannenbaum
(908) 740-1037
Courtney Ronaldo
(908) 740-6132
